Cargando…
Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study
BACKGROUND: Omalizumab is a fully humanized monoclonal antibody indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma. AIMS: The aim of this study was to evaluate social, healthcare expenditure and clinical outcomes changes after incorporating omali...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710309/ https://www.ncbi.nlm.nih.gov/pubmed/30684255 http://dx.doi.org/10.1007/s41669-019-0117-4 |
_version_ | 1783446322332827648 |
---|---|
author | Entrenas Costa, Luis Manuel Casas-Maldonado, Francisco Soto Campos, José Gregorio Padilla-Galo, Alicia Levy, Alberto Álvarez Gutiérrez, Francisco Javier Gómez-Bastero Fernández, Ana P. Morales-García, Concepción Gallego Domínguez, Rocío Villegas Sánchez, Gustavo Mateos Caballero, Luis Pereira-Vega, Antonio García Polo, Cayo Pérez Chica, Gerardo Martín Villasclaras, Juan José |
author_facet | Entrenas Costa, Luis Manuel Casas-Maldonado, Francisco Soto Campos, José Gregorio Padilla-Galo, Alicia Levy, Alberto Álvarez Gutiérrez, Francisco Javier Gómez-Bastero Fernández, Ana P. Morales-García, Concepción Gallego Domínguez, Rocío Villegas Sánchez, Gustavo Mateos Caballero, Luis Pereira-Vega, Antonio García Polo, Cayo Pérez Chica, Gerardo Martín Villasclaras, Juan José |
author_sort | Entrenas Costa, Luis Manuel |
collection | PubMed |
description | BACKGROUND: Omalizumab is a fully humanized monoclonal antibody indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma. AIMS: The aim of this study was to evaluate social, healthcare expenditure and clinical outcomes changes after incorporating omalizumab into standard treatment in the control of severe asthma. METHODS: In this multicentre retrospective study, a total of 220 patients were included from 15 respiratory medicine departments in the regions of Andalusia and Extremadura (Spain). Effectiveness was calculated as a 3-point increase in the Asthma Control Test (ACT) and a reduction in the annual number of exacerbations. The economic evaluation included both direct and indirect costs. Incremental cost-effectiveness ratio (ICER) was calculated. Results from the year before and the year after incorporation of omalizumab were compared. RESULTS: After adding omalizumab, improvement of lung function, asthma and rhinitis according to patient perception, as well as the number of exacerbations and asthma control measured by the ACT score were observed. Globally, both healthcare resources and pharmacological costs decreased after omalizumab treatment, excluding omalizumab cost. When only direct costs were considered, the ICER was €1712 (95% CI 1487–1995) per avoided exacerbation and €3859 (95% CI 3327–4418) for every 3-point increase in the ACT score. When both direct and indirect costs were considered, the ICER was €1607 (95% CI 1385–1885) for every avoided exacerbation and €3555 (95% CI 3012–4125) for every 3-point increase. CONCLUSIONS: Omalizumab was shown to be an effective add-on therapy for patients with persistent severe asthma and allowed reducing key drivers of asthma-related costs. |
format | Online Article Text |
id | pubmed-6710309 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-67103092019-09-09 Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study Entrenas Costa, Luis Manuel Casas-Maldonado, Francisco Soto Campos, José Gregorio Padilla-Galo, Alicia Levy, Alberto Álvarez Gutiérrez, Francisco Javier Gómez-Bastero Fernández, Ana P. Morales-García, Concepción Gallego Domínguez, Rocío Villegas Sánchez, Gustavo Mateos Caballero, Luis Pereira-Vega, Antonio García Polo, Cayo Pérez Chica, Gerardo Martín Villasclaras, Juan José Pharmacoecon Open Original Research Article BACKGROUND: Omalizumab is a fully humanized monoclonal antibody indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma. AIMS: The aim of this study was to evaluate social, healthcare expenditure and clinical outcomes changes after incorporating omalizumab into standard treatment in the control of severe asthma. METHODS: In this multicentre retrospective study, a total of 220 patients were included from 15 respiratory medicine departments in the regions of Andalusia and Extremadura (Spain). Effectiveness was calculated as a 3-point increase in the Asthma Control Test (ACT) and a reduction in the annual number of exacerbations. The economic evaluation included both direct and indirect costs. Incremental cost-effectiveness ratio (ICER) was calculated. Results from the year before and the year after incorporation of omalizumab were compared. RESULTS: After adding omalizumab, improvement of lung function, asthma and rhinitis according to patient perception, as well as the number of exacerbations and asthma control measured by the ACT score were observed. Globally, both healthcare resources and pharmacological costs decreased after omalizumab treatment, excluding omalizumab cost. When only direct costs were considered, the ICER was €1712 (95% CI 1487–1995) per avoided exacerbation and €3859 (95% CI 3327–4418) for every 3-point increase in the ACT score. When both direct and indirect costs were considered, the ICER was €1607 (95% CI 1385–1885) for every avoided exacerbation and €3555 (95% CI 3012–4125) for every 3-point increase. CONCLUSIONS: Omalizumab was shown to be an effective add-on therapy for patients with persistent severe asthma and allowed reducing key drivers of asthma-related costs. Springer International Publishing 2019-01-25 /pmc/articles/PMC6710309/ /pubmed/30684255 http://dx.doi.org/10.1007/s41669-019-0117-4 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Article Entrenas Costa, Luis Manuel Casas-Maldonado, Francisco Soto Campos, José Gregorio Padilla-Galo, Alicia Levy, Alberto Álvarez Gutiérrez, Francisco Javier Gómez-Bastero Fernández, Ana P. Morales-García, Concepción Gallego Domínguez, Rocío Villegas Sánchez, Gustavo Mateos Caballero, Luis Pereira-Vega, Antonio García Polo, Cayo Pérez Chica, Gerardo Martín Villasclaras, Juan José Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study |
title | Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study |
title_full | Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study |
title_fullStr | Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study |
title_full_unstemmed | Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study |
title_short | Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study |
title_sort | economic impact and clinical outcomes of omalizumab add-on therapy for patients with severe persistent asthma: a real-world study |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710309/ https://www.ncbi.nlm.nih.gov/pubmed/30684255 http://dx.doi.org/10.1007/s41669-019-0117-4 |
work_keys_str_mv | AT entrenascostaluismanuel economicimpactandclinicaloutcomesofomalizumabaddontherapyforpatientswithseverepersistentasthmaarealworldstudy AT casasmaldonadofrancisco economicimpactandclinicaloutcomesofomalizumabaddontherapyforpatientswithseverepersistentasthmaarealworldstudy AT sotocamposjosegregorio economicimpactandclinicaloutcomesofomalizumabaddontherapyforpatientswithseverepersistentasthmaarealworldstudy AT padillagaloalicia economicimpactandclinicaloutcomesofomalizumabaddontherapyforpatientswithseverepersistentasthmaarealworldstudy AT levyalberto economicimpactandclinicaloutcomesofomalizumabaddontherapyforpatientswithseverepersistentasthmaarealworldstudy AT alvarezgutierrezfranciscojavier economicimpactandclinicaloutcomesofomalizumabaddontherapyforpatientswithseverepersistentasthmaarealworldstudy AT gomezbasterofernandezanap economicimpactandclinicaloutcomesofomalizumabaddontherapyforpatientswithseverepersistentasthmaarealworldstudy AT moralesgarciaconcepcion economicimpactandclinicaloutcomesofomalizumabaddontherapyforpatientswithseverepersistentasthmaarealworldstudy AT gallegodominguezrocio economicimpactandclinicaloutcomesofomalizumabaddontherapyforpatientswithseverepersistentasthmaarealworldstudy AT villegassanchezgustavo economicimpactandclinicaloutcomesofomalizumabaddontherapyforpatientswithseverepersistentasthmaarealworldstudy AT mateoscaballeroluis economicimpactandclinicaloutcomesofomalizumabaddontherapyforpatientswithseverepersistentasthmaarealworldstudy AT pereiravegaantonio economicimpactandclinicaloutcomesofomalizumabaddontherapyforpatientswithseverepersistentasthmaarealworldstudy AT garciapolocayo economicimpactandclinicaloutcomesofomalizumabaddontherapyforpatientswithseverepersistentasthmaarealworldstudy AT perezchicagerardo economicimpactandclinicaloutcomesofomalizumabaddontherapyforpatientswithseverepersistentasthmaarealworldstudy AT martinvillasclarasjuanjose economicimpactandclinicaloutcomesofomalizumabaddontherapyforpatientswithseverepersistentasthmaarealworldstudy |